SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Interim Management Statement

28 Apr 2014 07:00

RNS Number : 6018F
Devro PLC
28 April 2014
 



For immediate release 28 April 2014

 

 

Devro plc

(the "Group")

 

Interim Management Statement

Devro plc, one of the world's leading manufacturers of collagen products for the food industry, today issues the following Interim Management Statement for the period from 1 January 2014 to date.

Devro's sales were strong in certain key markets such as Germany, Japan and China and the USA, but in some other markets were weaker. In total, volumes were behind last year for the period. Sales were affected by a variety of factors such as currency restrictions and devaluations in Latin America, European retail markets, the EU pork meat import ban in Russia and the impact of prior year price increases in Europe.

Currency against prior year remains at £5 million adverse on operating profits, as previously indicated, and £13 million on revenue.

Trading in the first quarter was below prior year but March showed signs of improvement, which have continued into April. On account of the current market situation, the Board has taken a more prudent view such that volumes and prices in 2014 are currently expected to be flat and, for that reason, has decided to bring forward immediately strategic plans to streamline Devro's manufacturing footprint. Over the next year, Devro will move from older, higher cost production lines to a greater proportion of manufacturing being on our most cost efficient technology. This decision, coupled with the revised expectation for sales for the year, is expected to reduce profits for 2014 by approximately £8 million.

Exceptional cash costs over the next two years relating to these changes are expected to total approximately £6 million together with non-cash costs of approximately £10 million.

Going forward, these actions are expected to reduce manufacturing costs by £4 million in 2015, giving Devro a lower cost and higher quality manufacturing base, better placed to meet the demands of its markets.

Our investment projects in the USA and China are progressing according to plan which will help reduce the group unit cost of manufacture still further from 2016. A US private placement was successfully completed on 17 April 2014 for a total of US$100 million of which US$50 million has been received and the remainder is due in June 2014. This will ensure long term funding is in place to support these two projects.

The Board remains confident that with a low cost manufacturing base and a world class product range Devro will be in a strong position to benefit from the growing demand for collagen casing driven by protein consumption worldwide.

ENDS

 

 

 

For further information, please contact:

 

Devro plc

Peter Page, Chief Executive

Simon Webb, Group Finance Director

 

 

 

Tel No: 020 7182 4960

 

Buchanan

Charles Ryland / Sophie McNulty/

Clare Akhurst

 

 

 

Tel No: 020 7466 5000

 

Notes to Editors

 

FTSE listed Devro is one of the world's leading providers of collagen casings to the food industry supplying a wide range of products and technical support to manufacturers of sausages, salamis, hams and other cooked meats. The Group employs 2,200 staff across the world and produces its casings from five manufacturing sites based in Scotland, Australia, the Czech Republic and the USA. Devro reported sales of £242.7 million and profit before tax (before exceptional items) of £38.8 million for the year ended 31 December 2013. Devro is a constituent of the FTSE4Good Index Series which recognises that the company's performance meets globally recognised corporate responsibility standards.

 

Further information on Devro can be found on the company's website: www.devro.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSZMGZDVNMGDZM
Date   Source Headline
1st Apr 20221:00 pmRNSBlock Listing Application
31st Mar 20229:57 amRNSDirector/PDMR Shareholding
25th Mar 20223:51 pmRNSAnnual Report & Accounts 2021 & Notice of 2022 AGM
2nd Mar 20227:00 amRNSFULL YEAR RESULTS
21st Jan 20223:17 pmRNSDirector/PDMR Shareholding
20th Jan 20225:39 pmRNSDirector/PDMR Shareholding
19th Jan 20225:23 pmRNSDirector/PDMR Shareholding
19th Jan 20227:00 amRNSTrading update
16th Dec 202112:14 pmRNSHolding(s) in Company
23rd Nov 20217:00 amRNSTrading Update
2nd Nov 20217:00 amRNSDirectorate Changes
29th Sep 20218:00 amRNSNotice of ESG Seminar
24th Aug 20218:48 amRNSHolding(s) in Company
24th Aug 20218:47 amRNSHolding(s) in Company
12th Aug 20215:55 pmRNSHolding(s) in Company
4th Aug 202111:19 amRNSDirector/PDMR Shareholding
29th Jul 20217:00 amRNSHalf-year Results
27th Jul 20214:57 pmRNSDirector/PDMR Shareholding
4th Jun 20219:05 amRNSDirector Declaration
5th May 20215:15 pmRNSDirector/PDMR Shareholding
4th May 20215:34 pmRNSDirector/PDMR Shareholding
29th Apr 20215:09 pmRNSResult of AGM
29th Apr 20217:00 amRNSTrading Update
15th Apr 20213:14 pmRNSDirector/PDMR Shareholding
13th Apr 20214:53 pmRNSDirector/PDMR Shareholding
26th Mar 20214:47 pmRNS2020 Annual Report and Notice of AGM
10th Mar 20215:04 pmRNSDirector/PDMR Shareholding
5th Mar 20214:45 pmRNSDirector/PDMR Shareholding
2nd Mar 20217:00 amRNSFULL YEAR RESULTS
20th Jan 20219:29 amRNSDirector/PDMR Shareholding
18th Jan 20217:00 amRNSTrading update
18th Dec 20202:12 pmRNSDirector/PDMR Shareholding
24th Nov 20207:00 amRNSTrading Update
22nd Oct 20207:00 amRNSDirectorate Changes
14th Oct 20207:00 amRNSDirectorate Appointment
7th Oct 202010:16 amRNSDirector/PDMR Shareholding
17th Aug 20207:00 amRNSDirector/PDMR Shareholding
29th Jul 20207:01 amRNSDirectorate Change
29th Jul 20207:00 amRNSHALF YEAR RESULTS
30th Jun 20207:00 amRNSAppointment of Corporate Broker
23rd Jun 20209:23 amRNSHolding(s) in Company
12th Jun 20208:27 amRNSDirector/PDMR Shareholding
15th May 202012:02 pmRNSPrice Monitoring Extension
12th May 202011:06 amRNSDirector/PDMR Shareholding
30th Apr 20202:39 pmRNSResult of AGM
29th Apr 20207:00 amRNSDirectorate Appointment
27th Apr 20204:54 pmRNSPublication of Articles of Association
27th Apr 20209:33 amRNSDirector/PDMR Shareholding
23rd Apr 20207:00 amRNSTrading Update
16th Apr 20204:59 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.